Sebastian is an associate member of the Ludwig Institute for Cancer Research in Oxford, Director of Functional Genomics at the Target Discovery Institute and adjunct Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. I am also an elected member of the Young Academy of the Austrian Academy of Sciences.
He studied Medical Biology at the University of Utrecht and received his Ph.D. at the Netherlands Cancer Institute in 2005 in the group of René Bernards. During his PhD je performed the first RNAi screen in human cells and worked on the functional annotation of ubiquitin proteases, which since then have emerged as a new drug target class. He was a postdoctoral fellow at The Broad Institute of MIT and Harvard, in the laboratory of Todd Golub and started his own group in 2007 in Vienna at CeMM. Here, they discovered the first mechanism of resistance to PI3K/mTOR inhibitors and developed isogenic cell models to discover novel drug-gene interactions. In November 2014, he joined the Ludwig Institute for Cancer Research in Oxford where he will continue to work on these topics. Sebastian Nijman retains an adjunct PI position at CeMM.